- Previous Close
13.10 - Open
13.01 - Bid 13.12 x --
- Ask 13.13 x --
- Day's Range
12.58 - 13.65 - 52 Week Range
6.50 - 14.72 - Volume
9,554,321 - Avg. Volume
12,795,976 - Market Cap (intraday)
7.573B - Beta (5Y Monthly) 0.31
- PE Ratio (TTM)
-- - EPS (TTM)
-0.60 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
InventisBio Co., Limited, a clinical stage biotech company, engages in the discovery and development of therapeutics for cancer and metabolic diseases in China and the United States. The company's drug candidates for the oncology therapeutic area include BPI-D0316, which is in Phase III clinical trial for the non-small cell lung cancer (NSCLS) indications; D-0502, which is in Phase I clinical trial for the breast cancer indications; and D-1553, which in Phase I clinical trial for NSCLS, colorectal cancer indications. Its drug candidates for the metabolic therapeutic area is D-0120, a Phase I and II clinical trial product for hyperuricemia and gout indications. The company has a collaboration agreement with Betta Pharmaceuticals. InventisBio Co., Limited was founded in 2013 and is headquartered in Pudong, China.
www.inventisbio.comRecent News: 688382.SS
View MorePerformance Overview: 688382.SS
Trailing total returns as of 1/3/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 688382.SS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 688382.SS
View MoreValuation Measures
Market Cap
7.57B
Enterprise Value
5.97B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
98.37
Price/Book (mrq)
4.36
Enterprise Value/Revenue
77.06
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-12.24%
Return on Equity (ttm)
-18.52%
Revenue (ttm)
77.51M
Net Income Avi to Common (ttm)
-348.02M
Diluted EPS (ttm)
-0.60
Balance Sheet and Cash Flow
Total Cash (mrq)
1.62B
Total Debt/Equity (mrq)
1.40%
Levered Free Cash Flow (ttm)
-243.31M